Financial Performance Highlights

Q2 FY27 Performance:

  • Revenue grew 30% YoY to ₹358 Cr (₹362 Cr net revenue from operations)
  • EBITDA grew 26% YoY to ₹52 Cr (₹39 Cr standalone, plus ₹13 Cr JV share)
  • EBITDA margin remained healthy
  • PAT stood at ₹24 Cr with PAT margin of 6.5%
  • EPS of ₹3.5

H1 FY27 Performance:

  • Revenue increased 26% YoY to ₹713 Cr (₹720 Cr net revenue from operations)
  • EBITDA grew 25% to ₹113 Cr (₹79 Cr standalone, plus ₹33 Cr JV share)
  • EBITDA margin stable at 15.8%
  • PAT of ₹56 Cr with PAT margin of 7.8%
  • EPS of ₹8.4

Business Segment Performance

Bio-based Specialty Materials:

  • H1 revenue increased 43% YoY to ₹382 Cr
  • Q2 revenue grew 42% YoY to ₹194 Cr
  • H1 EBITDA up 15% to ₹62 Cr
  • Q2 EBITDA increased 12% YoY to ₹28 Cr
  • Margin pressures due to increased costs and freight
  • Represents 55% of H1 revenue (up from 52% previously)

Sustainable & Performance Chemicals:

  • Q2 revenue grew 36% YoY to ₹167 Cr
  • H1 revenue grew 29% to ₹313 Cr
  • Q2 EBITDA increased 49% to ₹24 Cr
  • H1 EBITDA increased 40% to ₹51 Cr
  • Q2 margin expanded from 13.0% to 14.2% (124 bps improvement)
  • H1 margin expanded from 15.0% to 16.3%

Demerger Completion

The company completed its demerger into three listed entities:

  • India Glycols Limited: Continuing as pure-play chemicals business with FY26 revenue of ₹1,164 Cr and EBITDA of ₹169 Cr (14.5% margin)
  • IGL Spirits Limited: Spirits & Bio-fuels business with FY26 revenue of ₹2,801 Cr and EBITDA of ₹492 Cr (17.6% margin)
  • Ennature Biopharma Limited: Nutraceuticals & plant-based APIs with FY26 revenue of ₹246 Cr and EBITDA of ₹29 Cr (11.9% margin)

Share allocation: 1 IGL Spirits share for every 1 IGL share, 1 Ennature Biopharma share for every 3 IGL shares.

Operating Environment Impact

Key external factors affecting Q2 performance:

  • Brent crude increased from ~$72 to $98
  • Gulf supply shortages lifted ether and MEG prices temporarily
  • Input costs rose significantly: chemicals up 35-75%, drums and IBCs up 21-54%, freight approximately doubled
  • Bio-MEG price gap narrowed to about 2.5 times petro-MEG
  • Currency movements: Won up 14%, yen weak, INR near record low
  • Domestic challenges: Weak monsoon, gas rationing, RBI rate rise

Balance Sheet Position (as at September 2026)

  • Fixed Assets: ₹1,256 Cr
  • CWIP: ₹114 Cr
  • Trade Receivables: ₹76 Cr
  • Cash and Bank Balance: ₹15 Cr
  • Inventories: ₹554 Cr
  • Total Assets: ₹2,611 Cr
  • Shareholders' Fund: ₹1,258 Cr
  • Long Term Borrowings: ₹341 Cr
  • Short Term Borrowings: ₹484 Cr

Cash Flow Statement (H1 FY27)

  • Cash Flow from Operating Activities: ₹39 Cr
  • Cash Flow from Investing Activities: (₹95) Cr
  • Cash Flow from Financing Activities: ₹35 Cr
  • Net decrease in Cash: (₹21) Cr
  • Closing Cash Balance: ₹6 Cr

Business Outlook and Strategy

  • Positioned as largest bio-based specialty chemicals manufacturer globally
  • Structural shift towards specialty-led portfolio with higher value products
  • Strong growth visibility from customer additions and product innovation
  • Beneficiary of favorable industry dynamics and supply constraints in global markets
  • Performance chemicals emerging as key growth driver
  • Margin expansion expected through portfolio mix improvement
  • Novel technologies in development: CCUS, novel catalysis, CO₂ valorisation

Manufacturing and Operational Capabilities

  • Integrated 300-acre Kashipur manufacturing complex
  • Direct rail connectivity to ports (~1,500 km to Mundra, Pipavav, Nhava Sheva)
  • ~35% of cargo routed via ICD Kashipur
  • Multi-source feedstock flexibility
  • Backward integration with captive intermediates
  • Biomass cogeneration and zero-liquid-discharge operations